Skip to main content
Equibles
MEDS logo

MEDS · DataMeds AI, Inc. · Documents

Track MEDS — free

Use MEDS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.87 -0.08 (-8.70%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the date these unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 17, 2026
Market Cap
$2.66M
Shares
3.06M
Volume · Nov 12 155.41K Avg daily vol (3M) 6.43M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $23.34M up 28.7% 10-K filed Mar 20, 2026 Quarterly report FY2026 Q2 Revenue $1.78M down 77.2% 10-Q filed Aug 17, 2026 Latest results Financial results 8-K filed Aug 18, 2026
2026
Nov 5
Current report 8-K Events of Nov 3
Letter of Intent Terminated Without Share Issuance

DataMEDS terminated its October 19, 2026 letter of intent effective November 3, 2026, citing market conditions; no shares will be issued and no fees or obligations are owed. Separate REBOOT and PharmacyChain agreements remain in force.

Ended a material agreement, Regulation FD disclosure
6 source passages
On November 3, 2026, the Company provided written notice to EOS, Scilex, Datavault, HBA, THI and REBOOT terminating the LOI, effective immediately. TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc. (“DataMeds SI,” “DataMEDS” or the “Company”) (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx^™^ artificial intelligence platform and PharmacyChain^™^ blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 (“2^nd^ LOI”) with Datavault AI Inc. (“Datavault AI”) (NASDAQ:DVLT), Data Health Partners, Inc.’s (“DHP”) wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. (“EOS”), Scilex Holding Company (“Scilex”) and HealthBridge Advisors, LLC (“HealthBridge Advisors”) for the in-license or acquisition of IP in exchange for Company common stock due to market conditions. DataMEDS does not owe any fees or obligation as a result of the termination. As a result of the termination of the 2^nd^ LOI, DataMEDS will no longer be issuing any shares related to the 2^nd^ LOI. DataMEDS confirms that its exclusive license with REBOOT for the management of GLP-1 users, dated October 13, 2026, remains in full force and effect. Datavault AI for PharmacyChain^™^ manufacturer-to-patient blockchain-enabled smart contracts remains in full force and effect, in accordance with the terms of that agreement dated November 24, 2025. Open the document at this passage
Oct 26
Current report 8-K Events of Oct 21
Entered into a material agreement, Regulation FD disclosure

DataMeds AI entered a non-binding LOI to acquire QLPM and Health Lives Here assets and licenses, targeting a fourth quarter 2026 close, with REBOOT, EOS and Scilex receiving royalties of 6%, 5% and 5%.

Read from the first part of this long document
Oct 20
Current report 8-K Events of Oct 19
Regulation FD disclosure, Other events

DataMeds AI, Inc. regained compliance with Nasdaq Listing Rule 5550(b)(1) after stockholders’ equity exceeded $2,500,000; Nasdaq confirmed compliance on October 19, 2026, but warned delisting may follow if compliance is not evidenced in the next periodic report.

Oct 13
Current report 8-K
Other events

DataMeds AI, Inc. paid $450,000 in a settlement that extinguished approximately $19 million in liability and repurchased and extinguished 364,099 shares. It also licensed REBOOT Health AI, Inc.’s care management platform and issued 666,667 shares to REBOOT.

Oct 9
Registration statement S-1/A
Registration statement

DataMeds AI, Inc. proposes resale of up to 34,462,057 common shares by selling stockholders, with no proceeds from sales. It also acquired Helomics for 636,328 shares and a $1,363,672.00 convertible note due September 11, 2029.

Read from the first part of this long document
Sep 17
Current report 8-K Events of Sep 11
Other events AI summary on its way
Aug 17
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.78M ▼ 77.2% Net loss $18.36M Diluted EPS -$7.13
Aug 14
Current report 8-K
Other events AI summary on its way
Jul 29
Current report 8-K Events of Jul 27
Other events AI summary on its way
Jun 3
Current report 8-K/A Events of May 27
Current report AI summary on its way
Jun 2
Current report 8-K/A Events of May 27
Current report AI summary on its way
May 21
Current report 8-K
Other events AI summary on its way
May 19
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.56M ▼ 85.6% Net loss $7.74M Diluted EPS -$0.07
May 18
Current report 8-K
Other events AI summary on its way
Mar 20
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $23.34M ▲ 28.7% Net loss $101.27M Diluted EPS -$1.43
2025
Showing 1–50 of 97 documents
Key facts CIK 2030763 CUSIP 949503205 13F (30d) 9 filings 9 filers Visit website Investor relations